Sermorelin vs. CJC-1295/Ipamorelin: Choosing a Growth Hormone Peptide

Two Approaches to Growth Hormone Optimization

For adults interested in peptide-based growth hormone optimization, sermorelin and the CJC-1295/Ipamorelin combination are the two most commonly prescribed options. Both stimulate the pituitary gland to produce growth hormone naturally — a fundamentally different approach from direct HGH injection. However, they differ in potency, dosing, pricing, and how they may suit different patient profiles. This comparison is intended to help inform your conversation with a prescribing provider.

Sermorelin: The Conservative Starting Point

Sermorelin is a growth hormone-releasing hormone (GHRH) analog and is considered the most conservative peptide option for GH optimization. It has the longest prescribing history among growth hormone peptides and works through a single pathway — stimulating GHRH receptors on the pituitary. Sermorelin has a relatively short half-life, requiring nightly injection, and produces a GH pulse that aligns with the body's natural sleep-related release pattern. Pricing is typically $99 to $250 per month, making it one of the most affordable peptide options.

CJC-1295/Ipamorelin: The More Potent Stack

CJC-1295/Ipamorelin combines two peptides that stimulate GH release through complementary pathways — CJC-1295 through GHRH receptors and Ipamorelin through ghrelin receptors. This dual-pathway approach may produce a stronger and more sustained growth hormone pulse than either peptide alone. CJC-1295 (particularly the DAC variant) has a longer half-life than sermorelin, potentially allowing for less frequent dosing. However, the combined stack is typically more expensive at $200 to $400 per month.

Key Differences at a Glance

• •Potency: CJC/Ipamorelin is generally considered more potent due to dual-pathway stimulation
• •Pricing: Sermorelin is more affordable ($99-$250/mo vs. $200-$400/mo)
• •Dosing: Sermorelin requires nightly injection; CJC-1295 with DAC may allow less frequent dosing
• •Side effects: Both may cause water retention and injection site reactions; CJC/Ipa may increase hunger due to ipamorelin's ghrelin activity
• •Starting point: Sermorelin is often recommended for those new to peptide therapy
• •Both: Compounded, not FDA-approved, and require provider supervision

Which Should You Consider?

Sermorelin may be the better starting point for those new to peptide therapy, those on a tighter budget, or those who prefer a more conservative approach. CJC-1295/Ipamorelin may be more appropriate for those who have tried sermorelin and want a more potent protocol, those with specific body composition or recovery goals, or those willing to invest more in a potentially stronger GH response. Neither is inherently better — the right choice depends on individual goals, response, and provider recommendation.

Some providers start patients on sermorelin and escalate to CJC/Ipamorelin if the response is insufficient. Others may recommend the combination stack from the beginning depending on the patient's age, baseline GH levels, and treatment goals. Blood work — particularly IGF-1 levels — should be monitored with either protocol to ensure GH levels are responding appropriately without becoming excessive.